These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32819975)

  • 1. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
    Sheybani ND; Witter AR; Thim EA; Yagita H; Bullock TNJ; Price RJ
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue- and Temporal-Dependent Dynamics of Myeloablation in Response to Gemcitabine Chemotherapy.
    Kitelinger LE; Thim EA; Zipkowitz SY; Price RJ; Bullock TNJ
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional Theranostic Nanoparticles for Enhanced Tumor Targeted Imaging and Synergistic FUS/Chemotherapy on Murine 4T1 Breast Cancer Cell.
    Kang Z; Yang M; Feng X; Liao H; Zhang Z; Du Y
    Int J Nanomedicine; 2022; 17():2165-2187. PubMed ID: 35592098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
    Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
    Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
    J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
    Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
    Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
    Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
    J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
    Min DJ; He S; Green JE
    Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
    Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
    Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer.
    Bu Y; Liu Q; Shang Y; Zhao Z; Sun H; Chen F; Ma Q; Song J; Cui L; Sun E; Luo Y; Shu L; Jing H; Tan X
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):131949. PubMed ID: 38749890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
    Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
    Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
    Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
    Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
    J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
    Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
    Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
    Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
    Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer.
    Singh B; Maharjan S; Pan DC; Zhao Z; Gao Y; Zhang YS; Mitragotri S
    Biomaterials; 2022 Jan; 280():121302. PubMed ID: 34894584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.